Optical molecular imaging can differentiate metastatic from benign lymph nodes in head and neck cancer

Identification of lymph node (LN) metastasis is essential for staging of solid tumors, and as a result, surgeons focus on harvesting significant numbers of LNs during ablative procedures for pathological evaluation. Isolating those LNs most likely to harbor metastatic disease can allow for a more ri...

Full description

Saved in:
Bibliographic Details
Published inNature communications Vol. 10; no. 1; pp. 5044 - 10
Main Authors Nishio, Naoki, van den Berg, Nynke S., van Keulen, Stan, Martin, Brock A., Fakurnejad, Shayan, Teraphongphom, Nutte, Chirita, Stefania U., Oberhelman, Nicholas J., Lu, Guolan, Horton, Crista E., Kaplan, Michael J., Divi, Vasu, Colevas, A. Dimitrios, Rosenthal, Eben L.
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 06.11.2019
Nature Publishing Group
Nature Portfolio
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Identification of lymph node (LN) metastasis is essential for staging of solid tumors, and as a result, surgeons focus on harvesting significant numbers of LNs during ablative procedures for pathological evaluation. Isolating those LNs most likely to harbor metastatic disease can allow for a more rigorous evaluation of fewer LNs. Here we evaluate the impact of a systemically injected, near-infrared fluorescently-labeled, tumor-targeting contrast agent, panitumumab-IRDye800CW, to facilitate the identification of metastatic LNs in the ex vivo setting for head and neck cancer patients. Molecular imaging demonstrates a significantly higher mean fluorescence signal in metastatic LNs compared to benign LNs in head and neck cancer patients undergoing an elective neck dissection. Molecular imaging to preselect at-risk LNs may thus allow a more rigorous examination of LNs and subsequently lead to improved prognostication than regular neck dissection. Imaging metastatic disease burden in lymph nodes is important for surgical decision making. Here, the authors use an antibody-dye conjugate to distinguish between metastatic and benign lymph nodes in head and neck cancer.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2041-1723
2041-1723
DOI:10.1038/s41467-019-13076-7